elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Pricing
Log in
Sign up
Home
/
Subjects
/
Ipilimumab
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Ipilimumab
RIS
0.001
(Research Intensity Score)
Papers
316
Top papers
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
2019 · 3728 citations
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
2022 · 454 citations
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
2021 · 1211 citations
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
2018 · 4676 citations
Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma
2025 · 64 citations
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
2025 · 40 citations
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab–ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial
2024 · 44 citations
Neoadjuvant immunotherapy in mismatch-repair-proficient colon cancers
2025 · 20 citations
Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
2024 · 34 citations
Newest papers
Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
2026 · 1 citations
First-line systemic treatment for people with extensive-stage small cell lung cancer: a network meta-analysis
2026
Deep Response as a Novel Efficacy Endpoint in Hepatocellular Carcinoma
2026
The real-world safety profile of enfortumab vedotin with or without pembrolizumab: insights from a comparative analysis of FAERS
2026
First-Line Nivolumab Plus Ipilimumab in Inoperable Epithelioid Malignant Pleural Mesothelioma: Real-World Experience From an Indian Tertiary Care Center
2026
Immunological Significance of the ICI–PIT–ICI Sequence in Recurrent Oral Cancer: A Narrative Review with Illustrative Cases
2026
Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
2026 · 1 citations
Innovative immunotherapies for prostate cancer: understanding the synergies between checkpoint inhibition, CAR T-cell therapy, and next-generation therapeutic modalities
2026 · 1 citations
Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma
2025 · 64 citations
Browse all papers →
Ipilimumab's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Ipilimumab's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link